Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch
Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.
Withdrawal of the planned U.S. listing/registration is a material strategic pivot that can reset financing and timeline expectations.
Regentis shares surged after withdrawing its SEC Form F-1 for a proposed U.S. listing/financing, a direct corporate-action catalyst.
Likely elevated volatility; upside momentum may fade if investors interpret withdrawal as a delay or funding/market-access issue.
Background
The article is a daily roundup of biotech/healthcare gainers, highlighting: RGNT’s SEC Form F-1 withdrawal, CUPR’s FDA clearance for maggot debridement therapy, NTLA’s additional Phase 3 results for hereditary angioedema, and other notable movers (MYO, HIMS, TXG).
Why it matters
CUPR’s FDA clearance and NTLA’s additional Phase 3 positivity are direct fundamental catalysts. RGNT’s Form F-1 withdrawal is a material corporate/financing signal but lacks stated rationale. MYO and TXG appear more sentiment/financial-direction driven, while HIMS benefits from resolution of a semaglutide patent dispute.
Market relevance
Traders can treat CUPR and NTLA as catalyst-driven longs/hedges, while RGNT/HIMS require monitoring for follow-on details (financing rationale; settlement terms). MYO/TXG look more like momentum/financial-direction plays than fresh catalysts.
Market effects
Regulatory clearances and additional Phase 3 positivity reinforce near-term sentiment for biotech risk assets, especially in specialty therapeutics.
Primarily U.S.-listed biotech/healthcare names; could spill over to small/mid-cap biotech momentum baskets.
Limited direct global linkage beyond FDA-driven commercialization expectations and broader biotech risk appetite.
Alternative perspectives
Some of the biggest movers (e.g., RGNT, MYO, TXG) may be trading on headline momentum; without detailed rationale/metrics, follow-through may be fragile.
For RGNT, the withdrawal reason is not provided; for NTLA, the article omits efficacy/safety magnitude; for HIMS, settlement terms and ongoing regulatory/competitive constraints are unspecified.
Key entities
- companyRegentis Biomaterials Ltd.
Withdrew its SEC Form F-1 for a planned U.S. listing/financing; GelrinC is in a U.S. pivotal study.
- companyCuprina Holdings (Cayman) Ltd.
Received FDA clearance for MEDIFLY maggots for debridement of non-healing wounds.
- companyIntellia Therapeutics Inc.
Reported additional positive Phase 3 results for lonvo-z in hereditary angioedema; rolling BLA initiated.
- companyMyomo Inc.
Wearable medical robotics company; shares rose without specific new news in the article.
- companyHims & Hers Health Inc.
Wellness platform; shares rose after resolution of a Novo Nordisk semaglutide patent dispute.
